Co-stimulation With Ipilimumab to Enhance Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Patients With Metastatic Melanoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Ipilimumab (Primary) ; LN 144 (Primary) ; Cyclophosphamide; Fludarabine; Interleukin-2
- Indications Malignant melanoma
- Focus Adverse reactions
- 22 Dec 2017 Planned End Date changed from 30 Apr 2018 to 1 Feb 2019.
- 10 Jul 2017 Planned End Date changed from 30 Nov 2017 to 30 Apr 2018.
- 27 Jun 2017 According to an Iovance Biotherapeutics media release, Lion Biotechnologies has changed its name to Iovance Biotherapeutics.